Atripla

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instance_of gptkb:immunotherapy
gptkbp:administered_by oral tablet
gptkbp:approves gptkb:2006
gptkb:FDA
gptkbp:available_in gptkb:various_countries
gptkbp:brand gptkb:Atripla
gptkbp:clinical_trial Phase III trials
gptkbp:clinical_use long-term management of HIV
gptkbp:contains gptkb:tenofovir_disoproxil_fumarate
gptkb:efavirenz
gptkb:emtricitabine
gptkbp:contraindication pregnancy
severe liver disease
gptkbp:dosage_form once daily
gptkbp:drug_interactions CYP450 inducers
CYP450 inhibitors
gptkbp:financial_support available for adherence support
gptkbp:formulation fixed-dose combination
gptkbp:healthcare gptkb:tablet
requires prescription
https://www.w3.org/2000/01/rdf-schema#label Atripla
gptkbp:indication HIV-1 infection
gptkbp:is_monitored_by liver function tests
renal function tests
gptkbp:marketed_as gptkb:Bristol-Myers_Squibb
gptkbp:mechanism_of_action non-nucleoside reverse transcriptase inhibitor
gptkbp:packaging blister pack
gptkbp:patient_education importance of adherence
gptkbp:patient_population adults and children over 12 years
gptkbp:pharmacokinetics once daily dosing
inhibits HIV replication
gptkbp:previous_name efavirenz/emtricitabine/tenofovir
gptkbp:price varies by country
gptkbp:provides_guidance_on part of combination therapy
recommended in treatment-naive patients
gptkbp:regulatory_compliance approved in many countries
gptkbp:requires available online
gptkbp:research ongoing studies for long-term effects
gptkbp:safety_features generally well tolerated
gptkbp:side_effect dizziness
fatigue
nausea
rash
lactic acidosis
neuropsychiatric symptoms
gptkbp:storage room temperature
gptkbp:supply_chain managed by pharmaceutical companies
gptkbp:treatment reduces viral load
improves CD4 count
gptkbp:type_of_care important for efficacy
gptkbp:used_for treatment of HIV
gptkbp:bfsParent gptkb:Gilead_Sciences
gptkbp:bfsLayer 4